Comment on “Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T‐Cell Lymphoma”

Documenti analoghi

• Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
  di: Hiroyuki Inoue, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies
  di: Sven Stodtmann, et al.
  Pubblicazione: (2026)
• Population Pharmacokinetic Modeling and Exposure–Efficacy and Body Weight–Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma
  di: Yanan Zheng, et al.
  Pubblicazione: (2024)
• Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2025)
• Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma
  di: Fan Wu, et al.
  Pubblicazione: (2025)